Human metapneumovirus in lung transplant recipients: characteristics and outcomes

Infectious Diseases

Volumn 48, Issue 11-12, 2016, Pages 852-856

  Niggli, Fabian ^a   Huber, Lars C ^a   Benden, Christian ^a   Schuurmans, Macé M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adverse drug reactions; human metapneumovirus; lung transplantation; safety; shedding; treatment

Indexed keywords

HEMOGLOBIN; RIBAVIRIN; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CLINICAL ARTICLE; DRUG TOLERABILITY; FATIGUE; FEMALE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN METAPNEUMOVIRUS; HUMAN METAPNEUMOVIRUS INFECTION; LUNG TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; NAUSEA; NONHUMAN; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SHIVERING; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS SHEDDING; ISOLATION AND PURIFICATION; METAPNEUMOVIRUS; MIDDLE AGED; NASOPHARYNX; PARAMYXOVIRIDAE INFECTIONS; PATHOLOGY; RESPIRATORY TRACT INFECTIONS; SWITZERLAND; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; METAPNEUMOVIRUS; MIDDLE AGED; NASOPHARYNX; PARAMYXOVIRIDAE INFECTIONS; POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RIBAVIRIN; SWITZERLAND; TIME FACTORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; VIRUS SHEDDING; YOUNG ADULT;

EID: 84978512575     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.1080/23744235.2016.1204661     Document Type: Article

References (24)

1. E.M.Lenneke, S.F.Thijsen, L.van Elden,. Human metapneumovirus in adults. Viruses. 2013;5:87–110.
2. T.Fuehner, M.Dierich, C.Duesberg,. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antiviral Ther. 2011;16:733–740.
3. J.S.Kahn Epidemiology of human metapneumovirus. Clin Microbiol Rev. 2006;19:546–557.
4. Y.Matsuzaki, T.Itagaki, T.Ikeda,. Human metapneumovirus infection among family members. Epidemiol Infect. 2013;141:827–832.
5. E.E.Walsh, D.R.Peterson, A.R.Falsey Human metapneumovirus infections in adults:another piece of the puzzle. Arch Intern Med. 2008;168:2489–2496.
6. P.R.Wyde, S.N.Chetty, A.M.Jewell,. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 2003;60:51–59.
7. L.H.McCurdy, A.Milstone, S.Dummer Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745–753.
8. K.Raza, S.B.Ismailjee, M.Crespo,. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. 2007;26:862–864.
9. C.Renaud, H.Xie, S.Seo,. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013;19:1220–1226.
10. S.Y.Park, S.Baek, S.O.Lee,. Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection:analytic strategy using propensity scores. Antimicrob Agents Chemother. 2013;57:983–989.
11. M.M.Schuurmans, C.Benden, L.C.Huber Managing viral respiratory tract infections in lung transplant recipients. Eurasian J Pulmonol. 2014;16:144–149.
12. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO/NMH/NHD/MNM/11.1; 2011.
13. K.R.Talaat, R.A.Karron, B.Thumar,. Experimental infection of adults with recombinant wild-type human metapneumovirus. J Infect Dis. 2013;208:1669–1678.
14. C.M.Preiksaitis, J.M.Kuypers, C.E.Fishera,. A patient self-collection method for longitudinal monitoring of respiratory virus infection in solid organ transplant recipients. J Clin Virol. 2015;62:98–102.
15. C.R.De Lima, T.B.Mirandolli, L.C.Carneiro,. Prolonged respiratory viral shedding in transplant patients. Transpl Infect Dis. 2014;16:165–169.
16. P.Hopkins, K.McNeil, F.Kermeen,. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178:876–881.
17. A.R.Glanville, A.I.Scott, J.M.Morton,. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114–2119.
18. A.E.Gross, M.L.Bryson Oral ribavirin for the treatment of noninfluenza respiratory viral infections:a systematic review. Ann Pharmacother. 2015;49:1125–1135.
19. N.Kamar, J.Izopet, S.Tripon,. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370:1111–1120.
20. C.A.Naranjo, U.Busto, E.M.Sellers,. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
21. P.O.Bridevaux, J.D.Aubert, P.M.Soccal,. Incidence and outcomes of respiratory viral infections in lung transplant recipients:a prospective study. Thorax. 2014;69:32–38.
22. S.Shahda, W.G.Carlos, P.J.Kiel,. The human metapneumovirus:a case series and review of the literature. Transpl Infect Dis. 2011;13:324–328.
23. C.E.Fisher, C.M.Preiksaitis, E.D.Lease,. Symptomatic respiratory virus infection and chronic lung allograft dysfunction. Clin Infect Dis. 2016;62:313–319.
24. A.Dosanjh Respiratory metapneumoviral infection without co-infection in association with acute and chronic lung allograft dysfunction. J Inflamm Res. 2015;8:79–82.